This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
C9orf72-related ALS/FTD (C9orf72 expansions)
GGGGCC hexanucleotide repeat expansion in the non-coding sequence of the C9orf72 gene is associated with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) (Renton et al., 2011; DeJesus-Hernandez et al., 2011), of autosomal dominant inheritance. Generally, alleles with less than 25 repeats are considered normal and those with more than 60 pathogenic.
Globally, this variant represents the most common cause of sporadic and familial ALS (7% and 38% of cases, respectively), the most common cause of sporadic FTD (6% of cases) and one of the most common causes of familial FTD (25% of cases) (Majounie et al., 2012). In Spain, this variant is responsible for 27% of familial ALS, 3% of sporadic ALS, 30% of familial FTD, and 22.58% of sporadic FTD (García-Redondo et al., 2013; van der Zee et al., 2013). Carriers of this expansion are typically diagnosed with ALS, FTD, or both. Some carriers never develop the disease, which is consistent with incomplete penetrance. The initial manifestations can be pure ALS or FTD, and the appearance of other symptoms is normal throughout the course of the disease. Although there are no definitive clinical characteristics that would allow distinguishing these patients from carriers of ALS- or FTD-related mutations in other genes, this variant is usually associated with an earlier age of onset (regardless of initial symptoms), faster clinical course, shorter survival, bulbar onset (in the case of ALS), higher incidence of relatives with neurodegenerative diseases (especially dementia, in 35% of cases), parkinsonism (mainly rigid-akinetic type with focal dystonia and poor levodopa response), and an increased susceptibility to psychiatric symptoms, such as psychosis, early-onset delusions, paranoia, and late-onset hallucinations.
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
C9orf72-related ALS/FTD (C9orf72 expansions)
Turnaround time (TAT): 8 weeks
Ref. S-201805509
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20;72(2):245-56
https://www.ncbi.nlm.nih.gov/pubmed/21944778 - García-Redondo A, Dols-Icardo O, Rojas-García R, Esteban-Pérez J, Cordero-Vázquez P, Muñoz-Blanco JL, et al. Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum Mutat. 2013 Jan;34(1):79-82
https://www.ncbi.nlm.nih.gov/pubmed/22936364 - Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012 Apr;11(4):323-30
https://www.ncbi.nlm.nih.gov/pubmed/22406228 - Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257-68
https://www.ncbi.nlm.nih.gov/pubmed/21944779 - Van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat. 2013 Feb;34(2):363-73
https://www.ncbi.nlm.nih.gov/pubmed/23111906